January 30, 2019
Sumitomo Dainippon Pharma said on January 29 that it has earned Chinese regulatory approval for its atypical antipsychotic Latuda (lurasidone) for the treatment of schizophrenia. The Japanese drug maker filed an import drug license application in December 2015, and the...read more